Enhanced expression of the UROC28 gene in human breast cancer: Relationship to ERBB2 gene expression

Anticancer Research

Volumn 22, Issue 6 C, 2002, Pages 4087-4091

  Kamagata, Chinatsu ^a   Tsuji, Naoki ^a   Kondoh, Kei ^a   Sasaki, Masateru ^a   Kobayashi, Daisuke ^a   Yagihashi, Atsuhito ^a   Watanabe, Naoki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Diagnostic marker; ERBB2; Estradiol; Molecular targets; UROC28

Indexed keywords

ESTRADIOL; ESTROGEN; MESSENGER RNA;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE; ONCOGENE NEU; ONCOGENE UROC28; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0036875599     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. McPherson K, Steel MC and Dixon JM: ABC of breast disease. Breast cancer-epidemiology, risk factors, and genetics. Br Med J 321: 624-628, 2000.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
4. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V and Kitchen P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11: 1936-1942, 1993.
5. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson MC and Slamon DJ: Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53: 4960-4970, 1993.
6. Ravdin PM and Chamness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review. Gene 159: 19-27, 1995.
7. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver, ME and Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89: 4285-4289, 1992.
8. Pietras RJ, Pegram MD, Finn RS, Maneval DA and Slamon D J: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17: 2235-2249, 1998.
9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
10. An G, Ng AY, Meka CS, Luo G, Bright SP, Cazares L, Wright GL Jr and Veltri RW: Cloning and characterization of UROC28, a novel gene overexpressed in prostate, breast, and bladder cancers. Cancer Res 60: 7014-7020, 2000.
11. Holland PM, Abramson RD, Watson R and Gelfand DH: Detection of specific polymerase chain reaction product by utilizing the 5'-3' exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 88: 7276-7280, 1991.
12. Higuchi R, Fockler C, Dollinger G and Watson R: Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology 11: 1026-1030, 1993.
13. Yajima T, Yagihashi A, Kameshima H, Furuya D, Kobayashi D, Hirata K and Watanabe N: Establishment of quantitative reverse transcription - polymerase chain reaction assays for human telomerase-associated genes. Clin Chim Acta 290: 117-127, 2000.
14. Herbert V, Lau K S, Gottlieb CW and Bleicher SJ: Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25: 1375-1384, 1965.
15. Gudas JM, Nguyen H, Li T and Cowan KH: Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 55: 4561-4565, 1995.
16. Read LD, Keith D Jr, Slamon DJ and Katzenellenbogen BS: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947-3951, 1990.
17. Bates NP and Hurst HC: An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene 15: 473-481, 1997.
18. Dati C, Antoniotti S, Taverna D, Perroteau I and De Bortoli M: Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5: 1001-1006, 1990.
19. Russell KS and Hung MC: Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 52: 6624-6629, 1992.
20. Cohrs RJ, Goswami BB and Sharma OK: Down-regulation of c-myc, c-fos and erb-B during estrogen induced proliferation of the chick oviduct. Biochem Biophys Res Commun 150: 82-88, 1988.
21. Adnane J, Gaudray P, Simon MP, Simony-Lafontaine J, Jeanteur P and Theillet C: Proto-oncogene amplification and human breast tumor phenotype. Oncogene 4: 1389-1395, 1989.
22. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D and McGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332-4337, 1990.
23. Powles TJ, Tillye CR, Jones AL, Ashley SE, Treleaven J, Davey JB and McKinna JA: Prevention of breast cancer with tamoxifen- an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 26: 680-684, 1990.
24. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, Gray R, Gordon NH, Bengtsson NO and Sevelda P: Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 347: 1066-71, 1996.
25. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL and Horne CH: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118-121, 1992.
26. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S and Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81: 137-144, 1994.
27. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L and Lipton A: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129-1135, 1995.
28. Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H and Klijn JG: Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11-18, 1995.
29. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD and Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220-1226, 1999.